Hélène Sicard

In Vivo Immunomanipulation of Vγ9Vδ2 T Cells with a Synthetic Phosphoantigen in a Preclinical Nonhuman Primate Model

Hélène Sicard, Sophie Ingoure, Béatrice Luciani et al. · The Journal of Immunology · 2005 · 186 citations · Full text

Life Sciences, Immunology, Molecular Biology +13

IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial

M. Bagot, Pierluigi Porcu, Anne Marie‐Cardine et al. · The Lancet Oncology · 2019 · 157 citations · Full text

Medicine, Hematology, Oncology +13

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Julie Gertner-Dardenne, Cécile Bonnafous, Christine Bezombes et al. · Blood · 2009 · 140 citations · Full text

Life Sciences, Immunology, Oncology +16

Phosphoantigen/IL2 Expansion and Differentiation of Vγ2Vδ2 T Cells Increase Resistance to Tuberculosis in Nonhuman Primates

Crystal Y. Chen, Shuyu Yao, Dan Huang et al. · PLoS Pathogens · 2013 · 127 citations · Full text

Life Sciences, Immunology, Infectious Diseases +15

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

Jaafar Bennouna, Vincent Lévy, Hélène Sicard et al. · Cancer Immunology Immunotherapy · 2010 · 102 citations · Full text

Medicine, Immunology, Pharmacology +11